AKR1D1
3-oxo-5-beta-steroid 4-dehydrogenase
Protein Summary
Efficiently catalyzes the reduction of progesterone, androstenedione, 17-alpha-hydroxyprogesterone and testosterone to 5-beta-reduced metabolites. The bile acid intermediates 7-alpha,12-alpha-dihydroxy-4-cholesten-3-one and 7-alpha-hydroxy-4-cholesten-3-one can also act as substrates. The enzyme encoded by this gene is responsible for the catalysis of the 5-beta-reduction of bile acid intermediates and steroid hormones carrying a delta(4)-3-one structure. Deficiency of this enzyme may contribute to hepatic dysfunction. Three transcript variants encoding different isoforms have been found for this gene. Other variants may be present, but their full-length natures have not been determined yet. [provided by RefSeq, Jul 2010]
- ENST00000242375
- ENSP00000242375
- ENSG00000122787
- ENST00000411726
- ENSP00000402374
- ENST00000432161
- ENSP00000389197
- SRD5B1
- CBAS2
- SRD5B1
- 3o5bred
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 0.88 | ||
cell type or tissue | 0.62 | ||
protein domain | 0.58 | ||
co-expressed gene | 0.57 | ||
disease | 0.54 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 107.77 (req: < 5)
Gene RIFs: 28 (req: <= 3)
Antibodies: 212 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 107.77 (req: >= 5)
Gene RIFs: 28 (req: > 3)
Antibodies: 212 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 16
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0